<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="371054">
  <stage>Registered</stage>
  <submitdate>8/07/2016</submitdate>
  <approvaldate>13/07/2016</approvaldate>
  <actrnumber>ACTRN12616000933459</actrnumber>
  <trial_identification>
    <studytitle>Assessment of the use of spironolactone on the endothelial glycocalyx in high blood pressure</studytitle>
    <scientifictitle>Assessment of spironolactone on the endothelial glycocalyx in hypertension</scientifictitle>
    <utrn>U1111-1185-1956</utrn>
    <trialacronym>ASGARD</trialacronym>
    <secondaryid>ASGARD E35-2015</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Hypertension</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Hypertension</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Spironolactone 25mg, oral tablet, once daily. Adherence to be monitored by questionnaire and return of empty drug packets.</interventions>
    <comparator>Compared to patients receiving indapamide 2.5mg, oral tablet, daily. Adherence to be monitored by questionnaire and return of empty drug packets.</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Change in glycocalyx parameters by:
1. Glycocheck value (sublingual camera measurement of the glycocalyx)
2. ELISA of syndecan-1 on serum samples
3. ELISA of hyaluronan on serum samples</outcome>
      <timepoint>3 months post commencement of study drug</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Change in markers of endothelial dysfunction by:
1. ELISA of von Willebrand Factor on serum samples
2. ELISA of vascular cell adhesion molecule-1 (VCAM-1) on serum samples
3. Urinary microalbuminuria </outcome>
      <timepoint>3 months post commencement of study drug</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Hypertension on 24-hr ambulatory blood pressure monitoring (&gt;140/90mmHg)
and/or hypertensive event e.g. stroke
Microalbuminuria (spot urine ACR &gt; 3 mg/mmol)</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Malignancy, pregnancy, inability to consent, known haematological disorders, eGFR &lt;60</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Sealed opaque envelopes</concealment>
    <sequence>Computer software</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods>Based on a previously published article (Nieuwdorp et al, J Appl Physiol 2008), the number required to detect a 0.2micrometre difference in the glycocalyx for a significance level of 5% and power of 80% in a paired design (i.e. measuring outcomes before and after an intervention) is n=10. To factor in drop-outs, we plan to recruit n=15 in each arm (total 30).</statisticalmethods>
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>15/07/2016</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>30</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Withdrawn</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason>Participant recruitment difficulties</withdrawnreason>
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Box Hill Hospital - Box Hill</hospital>
    <hospital>Maroondah Hospital - Ringwood East</hospital>
    <hospital>Angliss Hospital - Upper Ferntree Gully</hospital>
    <postcode>3128 - Box Hill</postcode>
    <postcode>3135 - Ringwood East</postcode>
    <postcode>3156 - Upper Ferntree Gully</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Department of Renal Medicine, Box Hill Hospital</primarysponsorname>
    <primarysponsoraddress>Department of Renal Medicine, Box Hill Hospital, Level 2, 5 Arnold Street, Box Hill 3128, Victoria</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>Eastern Clinical Research Unit, Monash Univeresity</fundingname>
      <fundingaddress>Level 2, 5 Arnold Street, Box Hill 3128, Victoria</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The glycocalyx is a particle that is important in maintaining blood vessel health. High blood pressure is common, closely related to salt regulation, and affects the health of blood vessels. Animal studies have shown that the glycocalyx is affected in high blood pressure. Laboratory studies indicate that the use of spironolactone, a common blood pressure medication, can offset the effects of a high-salt environment on the glycocalyx. The purpose of this study is to assess if the glycocalyx is affected in people who have high blood pressure, whether the glycocalyx can be improved with good blood pressure control, and whether spironolactone has any additional protective benefits on the glycocalyx. </summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Eastern Health HREC</ethicname>
      <ethicaddress>Level 2, 5 Arnold Street, Box Hill 3128, Victoria</ethicaddress>
      <ethicapprovaldate>7/07/2016</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate>19/05/2016</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Hui Liew</name>
      <address>Department of Renal Medicine, Box Hill Hospital, Level 2, 5 Arnold Street, Box Hill 3128, Victoria</address>
      <phone>+61390918870</phone>
      <fax />
      <email>hui.liew@easternhealth.org.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Hui Liew</name>
      <address>Department of Renal Medicine, Box Hill Hospital, Level 2, 5 Arnold Street, Box Hill 3128, Victoria</address>
      <phone>+61390918870</phone>
      <fax />
      <email>hui.liew@easternhealth.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Hui Liew</name>
      <address>Department of Renal Medicine, Box Hill Hospital, Level 2, 5 Arnold Street, Box Hill 3128, Victoria</address>
      <phone>+61390918870</phone>
      <fax />
      <email>hui.liew@easternhealth.org.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>